VIRTUAL WORKSHOP SERIES
Session 2: Future efficacy trial design approaches
HIV prevention is evolving rapidly with the roll out of new tools such as pre-exposure prophylaxis (PrEP) and treatment as prevention making a significant contribution towards controlling the epidemic.
As a result, the design and conduct of the next generation of prevention trials is impacted and is further affected by the outcomes of ongoing HIV prevention efficacy trials – including oral and injectable antiretrovirals, passively infused monoclonal antibodies, and HIV vaccines.
The second session of the virtual workshop aims to reflect on future trial designs for ARV-based prevention strategies and HIV vaccines. This session is supported by a further six bite-size presentations and two panel discussions of the current scientific approaches for establishing efficacy of vaccines in the broader context or Pre-Exposure Prophylaxis (PrEP).
PANEL DISCUSSION 2A – Friday 06 November 2020.
Future Design Approaches For Trials Of Antiretroviral-Based Prevention Strategies
PANEL DISCUSSION 2B – Wednesday 18 November 2020.
Future Design Approaches for HIV Vaccine Efficacy Trials
| Presentation | Presenter |
|---|---|
| Inferring HIV incidence using incidence of other STIs | Jared Baeten, M.D., Ph.D. – University of Washington, Seattle, USA. |
| Cross-sectional HIV incidence estimation using recent infection assays and algorithms – A statistical perspective | Eduard Grebe, Ph.D – Vitalant Research Institute, San Francisco, USA. |
| Cross-sectional incidence assays to infer population incidence – Clinical trial perspective | Sinéad Delany-Moretlwe, MBBCh Ph.D. DTM&H – Wits RHI, South Africa. |
| Using of a surrogate endpoint in licensure of pneumococcal vaccines | David Radley, M.Sc. – Pfizer Inc. – New York, USA. |
| A case study in using extra-trial data to infer placebo incidence | Mia Moore, Ph.D. – Fred Hutchinson Cancer Research Center, Seattle, USA. |
| Future directions for more granular estimation of HIV incidence | Jeffrey W. Eaton, Ph.D. – Imperial College London, UK. |
Inferring HIV incidence using incidence of other STIs (S2-01)
Jared Baeten, M.D., Ph.D.
University of Washington, Seattle, USA.
Submit your questions here.
Cross-sectional incidence assays to infer population incidence (S2-02)
Eduard Grebe, Ph.D.
Vitalant Research Institute, San Francisco, USA.
Submit your questions here.
Cross-sectional incidence assays to infer population incidence(S2-03)
Sinéad Delany –Moretwe, MBBCh, Ph.D., DTM&H
Wits RHI, South Africa.
Submit your questions here.
Using of a surrogate endpoint in licensure of pneumococcal vaccines (S2-04)
David Radley, M.Sc.
Pfizer Inc.
Submit your questions here.
A case study in using extra-trial data to infer placebo incidence (S2-05)
Mia Moore, Ph.D.
Fred Hutchinson Cancer Research Center, Seattle, USA.
Submit your questions here.
Incorporation of trial incidence data into model estimate (S2-06)
Jeffrey W. Eaton, Ph.D.
Imperial College London, London, UK.
Submit your questions here.
About
The Global HIV Vaccine Enterprise (the Enterprise) unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of—and future access to—an HIV vaccine.
Global HIV Vaccine Enterprise
International AIDS Society
Avenue de France 23
CH-1202 Geneva
Switzerland
Contact Us
